ADDED
As of August 22, 2025, the nu mber of outstanding shares of the registrant s common stock, $0.001 par value, was 112,677,147 .
Advanced architecture that accommodates third party surface guidance interfaces to support effective positioning of the patient and monitoring of the accuracy of that positioning throughout treatment, and enable deep inspiration breath hold ( DIBH ) for highly accurate and precise breast cancer treatments.
We believe our current technologies and our future innovations can help to achieve this.
Many of the countries in these regions are not highly developed at this time and therefore sales opportunities may be limited.
In addition, we recently introduced Accuray Helix, a CT-guided helical radiotherapy system, to help address gaps in patient access to radiation medicine.
The Helix system combines affordability with automation and tools for enhancing the speed of planning and delivery of radiation.
In fiscal 2022, we entered into an agreement with C-RAD to provide customers with a solution to enable surface guided radiation therapy ( SGRT ) and DIBH using the C-RAD Catalyst+ HD and Radixact System.
Additionally, we entered into an agreement with Limbus AI (now Radformation) to augment our adaptive radiotherapy capabilities by leveraging Limbus AI-driven autocontouring algorithms.
Our suite of radiation delivery devices includes the CyberKnife System and our next generation TomoTherapy platform-based solutions, including the Radixact System.
Robotic Radiation Delivery Solutions The CyberKnife platform is the only robotic, full-body SRS and SBRT delivery device on the market.
REMOVED
As of August 31, 2024, the number of outstanding shares of the registrant s common stock, $0.001 par value, was 100,267,900 .
Advanced architecture that accommodates third party surface guidance interfaces that can enable deep inspiration breath hold ( DIBH ) for highly accurate and precise breast treatments.
We endeavor to achieve this goal by expanding the clinical options for healthcare providers, helping them offer the best radiation treatment for each patient and by providing patients with treatment tailored to their specific needs.
Many of these countries however, are not highly developed at this time and therefore, sales opportunities may be limited.
In fiscal 2021, we announced a collaboration with Brainlab to enhance and expand the CyberKnife platform s capabilities for the neuro-radiosurgery market.
Our suite of radiation delivery devices includes the CyberKnife System and our next generation TomoTherapy platform, the Radixact System.
The CyberKnife Platform The CyberKnife platform is the only robotic, full-body SRS and SBRT delivery device on the market.
The CyberKnife S7 System has the option of fixed collimators plus the Iris Variable Aperture Collimator and/or InCise multi-leaf collimators ( MLC ).
Using our Synchrony real-time target tracking with dynamic delivery technology and computer controlled robotic mobility, the CyberKnife platform is designed to deliver radiation from a wide array of beam angles and autonomously track, detect and correct for even the slightest tumor and patient movement in real time throughout the entire treatment.
The main components and options of the CyberKnife platform include: compact X band linear accelerator; robotic manipulator arm, real time image guidance system with continuous target tracking and correction.